Citadel Advisors’s AYTU BioPharma AYTU Stock Holding History

Citadel Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,605	Closed	-$17K	–	14856
2022 Q3	$17K	Sell	4,605 -2,770	-38%	-$21K	﹤0.01%	12125
2022 Q2	$102K	Buy	7,375 +2,855	+63%	+$36.5K	﹤0.01%	11394
2022 Q1	$98K	Sell	4,520 -1,045	-19%	-$26K	﹤0.01%	12300
2021 Q4	$150K	Buy	5,565 +3,661	+192%	+$158K	﹤0.01%	12253
2021 Q3	$110K	Buy	1,904 +64	+3%	+$4.8K	﹤0.01%	12753
2021 Q2	$184K	Buy	+1,840	New	+$216K	﹤0.01%	12253

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's AYTU Position: Q2 2026 in Review

Citadel Advisors increased its AYTU BioPharma (AYTU) stake by 34% in Q2 2026, buying an estimated $29.7K and bringing the position to 49,414 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #12653.

Citadel Advisors first reported a position in AYTU in Q1 2018 and has held it in 18 quarters since. The position peaked at $500K in Q4 2020. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

Citadel Advisors held 49,414 shares of AYTU BioPharma worth $106K as of Q2 2026.
Citadel Advisors bought 12,573 AYTU BioPharma shares in Q2 2026, an estimated $29.7K.
AYTU BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12653 holding.
Citadel Advisors first reported a position in AYTU BioPharma in Q1 2018 and has held it in 18 quarters since.
Citadel Advisors's AYTU BioPharma position peaked at $500K in Q4 2020.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.